A Study to Evaluate the Cancer Related Pro-Inflammatory Response as a Stratifying Biomarker of Sorafenib Induced Survival in Patients With Advanced Hepatocellular Carcinoma (HCC)

Trial Profile

A Study to Evaluate the Cancer Related Pro-Inflammatory Response as a Stratifying Biomarker of Sorafenib Induced Survival in Patients With Advanced Hepatocellular Carcinoma (HCC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 02 Mar 2017 Results published in the Alimentary Pharmacology and Therapeutics.
    • 16 May 2016 New trial record
    • 17 Apr 2016 Results (N=442) assessing biomarkers to predict sorafenib induced survival benefit presented at The International Liver Congress™ 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top